“Please take notes if you want to, but I’m going to give you an audio-recording of this meeting to take home”

For the majority of newly diagnosed prostate cancer patients, the first meeting with their physician after diagnosis presents them with more information than they are able to assimilate easily … and many patients don’t have the necessary scientific or medical background to understand everything they are being told — even if they hear it all. … READ MORE …

Transrectal biopsy and the increasing risk for procedure-related infection

According to a paper presented at the recent meeting of the European Association of Urology in Madrid, Spain, there seems to be a significant and ongoing rise in the global risk for infections associated with prostate biopsy (and particularly with the transrectal prostate biopsy). … READ MORE …

Vitamin D as a treatment for low-risk prostate cancer? Not based on these data!

A presentation at a meeting of the American Chemical Society in Denver earlier this week suggested the possibility that men who took 4,000 IU of vitamin D every day for 60 days prior to a radical prostatectomy did better than similar men taking a placebo. … READ MORE …

How much time is there to make decisions about treatment for low-risk patients?

In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 = 6 or lower) had plenty of time to come to a good decision about their management options, and did not need to rush such decisions. … READ MORE …

Do new, prospective data mean the 4KScore test is “proven” for use in prime time?

According to data from a large, prospective, multi-institutional trial carried out here in the USA, the 4KScore test has shown a high degree of ability to accurately identify men with a Gleason score of 3 + 4 = 7 or higher which was subsequently confirmed on prostate biopsy. … READ MORE …

A rising incidence of intermediate- and higher-risk prostate cancer … but what does this mean?

According to another paper to be presented at the Genitourinary Cancers Symposium in Orlando, Florida, that started this morning, there was a 6 percent increase in the proportion of patients being diagnosed with intermediate- or higher-risk prostate cancers between 2011 and 2013. … READ MORE …

The optimization of risk assessment for management of prostate cancer

According to information from the Medical University of Vienna (in Austria) and Vienna General Hospital, researchers at these centers have been developing what they believe to be a smarter set of strategies for assessing prostate cancer risk and subsequent treatment, when this is needed. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,324 other followers